The agency reported actions against a biotech company and two large stem cell clinics over unapproved treatments, a move it said was necessary to make way for speedier approval of legitimate therapies.
SHEILA KAPLAN and DENISE GRADY, New York Times
Mon, 08/28/2017 - 11:19am
The agency reported actions against a biotech company and two large stem cell clinics over unapproved treatments, a move it said was necessary to make way for speedier approval of legitimate therapies.